RECRUITING

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Background: Cancer has a major impact in the United States and across the world. In 2015, over 1.5 million new cases of cancer were diagnosed in the U.S. Researchers want to study samples from people with cancer or a pre-malignant condition. They hope to develop more effective treatments. Objective: To better understand the biology of malignancies and why certain cancers respond differently to treatment. Eligibility: Adults at least 18 years old with cancer or a pre-cancerous condition. Design: Participants will be screened with a medical history, physical exam, and blood tests. Their diagnosis will be confirmed by the NCI Laboratory of Pathology. Participants will send tissue blocks or slides from their original tumor biopsy. At least once, participants will have a medical history, physical exam, and blood and urine tests. Participants may have the following tests. They may have them more than once: Apheresis. A needle in one arm removes blood. Blood is run through a machine and the sample cells are taken out. The rest of the blood is returned by a needle in the other arm. Bone marrow aspiration and biopsy. The hipbone will be numbed. A needle will be put into the hipbone. Bone marrow will be taken out through the needle. Piece of cancer tissue taken by a needle and syringe. Computed tomography (CT) scan, magnetic resonance imaging (MRI) and/or positron emission tomography (PET) scan or ultrasound to help locate their tumor. For the scans, they lie in a machine that takes pictures. A small piece of skin removed. Participants will be contacted by phone once a year to find out how they are doing.

Official Title

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

Quick Facts

Study Start:2016-04-11
Study Completion:2032-12-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT02682667

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 120 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Diagnosis of cancer, a premalignant/neoplastic condition or disease (such as an immunodeficiency) that increases the risk of being diagnosed with a cancer or premalignant/neoplastic condition
  2. 2. Age \>=18 years of age
  3. 3. ECOG performance status of 0-3.
  4. 1. Hemoglobin \>= 8 mg/dL and platelet count \> 75 K/microL
  5. 2. Weight \>= 48 kg
  6. 3. Central line in place or adequate venous access
  1. 1. Active concomitant medical or psychological illnesses that may increase the risk to the subject.
  2. 2. Inability to provide informed consent
  3. 3. Pregnant or breastfeeding women

Contacts and Locations

Study Contact

Scott M Norberg, D.O.
CONTACT
(301) 275-9668
scott.norberg@nih.gov

Principal Investigator

Scott M Norberg, D.O.
PRINCIPAL_INVESTIGATOR
National Cancer Institute (NCI)

Study Locations (Sites)

National Institutes of Health Clinical Center
Bethesda, Maryland, 20892
United States

Collaborators and Investigators

Sponsor: National Cancer Institute (NCI)

  • Scott M Norberg, D.O., PRINCIPAL_INVESTIGATOR, National Cancer Institute (NCI)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2016-04-11
Study Completion Date2032-12-01

Study Record Updates

Study Start Date2016-04-11
Study Completion Date2032-12-01

Terms related to this study

Keywords Provided by Researchers

  • Apheresis Products
  • Immunological
  • Diverse Malignan
  • Premalignant
  • Protein
  • Natural History

Additional Relevant MeSH Terms

  • Multiple Myeloma
  • Lymphoma, Non-Hodgkin
  • Leukemia-Lymphoma, Adult T-Cell
  • Hodgkin Disease
  • Non-Small Cell Lung Cancer